GSK moved to reduce capacity in Germany as demand for egg-based flu vaccines declined, telling a spokesperson Endpoints News it is closing a factory and laying off about 650 workers. The decision follows a “rigorous review” and signals continued portfolio and manufacturing optimization as vaccine demand evolves. The move matters for biotech planning because it affects supply expectations and can shift near-term production footprints for vaccine supply chains, particularly for flu formulations reliant on egg-based manufacturing.